(APYX) Apyx Medical - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03837C1062
APYX: Generators, Handpieces, Plasma Technology, Surgical, Energy Devices
Apyx Medical Corporation, a leader in energy-based medical technology, specializes in the development and manufacturing of advanced surgical devices. The company operates through two primary segments: Advanced Energy, which focuses on its proprietary Helium Plasma Technology, and Original Equipment Manufacturing (OEM), which provides custom solutions for medical device companies. Its flagship product, the Helium Plasma Generator, delivers precise RF energy and helium plasma for cutting, coagulating, and ablating soft tissue in both open and minimally invasive surgical procedures. These products are marketed under the Renuvion brand in the cosmetic surgery market and the J-Plasma brand in the hospital surgical market. Additionally, the company designs and manufactures hand pieces for laparoscopic and open procedures, as well as OEM generators and accessories. Formerly known as Bovie Medical Corporation, Apyx Medical Corporation rebranded in January 2019 to reflect its strategic shift toward innovative energy-based technologies. Founded in 1982, the company is headquartered in Clearwater, Florida.
Over the next three months, Apyx Medical Corporation is expected to face headwinds as its stock price currently trades below its 20-day, 50-day, and 200-day moving averages, indicating bearish momentum. The average true range (ATR) of 0.12 suggests limited volatility, which may constrain significant price movement in either direction. Fundamental analysis highlights a market cap of $44.80M, with a price-to-sales (P/S) ratio of 0.92, which may indicate undervaluation relative to its revenue. However, the price-to-book (P/B) ratio of 4.52 signals a premium relative to its book value. With no P/E ratio available due to lack of earnings, investors may remain cautious. The companys focus on minimally invasive surgical solutions and its OEM partnerships could drive long-term growth, but near-term challenges may persist.
Additional Sources for APYX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
APYX Stock Overview
Market Cap in USD | 44m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1987-01-01 |
APYX Stock Ratings
Growth 5y | -66.3% |
Fundamental | -55.8% |
Dividend | 0.0% |
Rel. Strength Industry | -40.4 |
Analysts | 3.5/5 |
Fair Price Momentum | 0.77 USD |
Fair Price DCF | - |
APYX Dividends
No Dividends PaidAPYX Growth Ratios
Growth Correlation 3m | -85.6% |
Growth Correlation 12m | -6.4% |
Growth Correlation 5y | -72.2% |
CAGR 5y | -25.67% |
CAGR/Max DD 5y | -0.27 |
Sharpe Ratio 12m | -1.01 |
Alpha | -53.77 |
Beta | 2.23 |
Volatility | 94.63% |
Current Volume | 95k |
Average Volume 20d | 28.2k |
As of March 14, 2025, the stock is trading at USD 1.04 with a total of 95,020 shares traded.
Over the past week, the price has changed by -11.86%, over one month by -25.71%, over three months by -38.10% and over the past year by -40.57%.
No, based on ValueRay Fundamental Analyses, Apyx Medical (NASDAQ:APYX) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -55.80 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of APYX as of March 2025 is 0.77. This means that APYX is currently overvalued and has a potential downside of -25.96%.
Apyx Medical has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold APYX.
- Strong Buy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, APYX Apyx Medical will be worth about 0.9 in March 2026. The stock is currently trading at 1.04. This means that the stock has a potential downside of -15.38%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3 | 188.5% |
Analysts Target Price | 3 | 188.5% |
ValueRay Target Price | 0.9 | -15.4% |